Free Trial
Srikripa Devarakonda

Srikripa Devarakonda Analyst Performance

Biotech Equity Analyst at Truist Financial

Srikripa Devarakonda is a stock analyst at Truist Financial in the medical sector, covering 8 publicly traded companies. Over the past year, Srikripa Devarakonda has issued 11 stock ratings, including buy and hold recommendations. While full access to Srikripa Devarakonda's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Srikripa Devarakonda's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 4 Years
Buy Recommendations
69.23% 9 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.2%9 ratings
Hold30.8%4 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Srikripa Devarakonda at Truist Financial, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
6 companies
NYSE
25.0% of companies on NYSE
2 companies

Srikripa Devarakonda, an analyst at Truist Financial, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Srikripa Devarakonda of Truist Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
62.5%
LARGE CAP PHARMA
2 companies
25.0%
PHARMACEUTICAL PREPARATIONS
1 company
12.5%

Srikripa Devarakonda's Ratings History at Truist Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8/11/2025Lower Price Target$559.54$812.00Buy
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Boost Price Target$77.98$79.00Hold
Incyte Corporation stock logo
INCY
Incyte
5/27/2025Boost Price Target$65.57$73.00Hold
Arvinas, Inc. stock logo
ARVN
Arvinas
5/5/2025Reiterated Rating$7.72$11.00Hold
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/30/2025Lower Price Target$592.47$940.00Buy
Biogen Inc. stock logo
BIIB
Biogen
4/29/2025Lower Price Target$120.86$199.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/23/2025Lower Price Target$589.00$975.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
4/9/2025Lower Price Target$9.76$25.00Buy
Biogen Inc. stock logo
BIIB
Biogen
2/13/2025Lower Price Target$133.43$210.00Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/3/2025Boost Price Target$814.06$1,038.00Buy
AbbVie Inc. stock logo
ABBV
AbbVie
2/3/2025Boost Price Target$189.52$217.00Buy